Sponsors (2)
The bill channels multi-year, flexible funding through intermediaries to enable high‑risk, ambitious biomedical research and institutional diversity, but does so at the risk of concentrating federal R&D dollars, restricting recipients' access to other grants, and increasing agency discretion and administrative burdens.
Scientists and research institutions will receive predictable, large-scale 7-year awards ($5M–$50M) that enable ambitious, high-risk biomedical projects requiring sustained support.
Nonprofit intermediaries can channel funds to early-stage, high-risk U.S.-based teams that are less likely to obtain standard NIH grants, increasing the chance of breakthrough discoveries and faster translation to practice.
Smaller planning awards ($1M–$5M for 1–3 years) lower barriers to forming new scientific institutions and projects, encouraging institutional diversity and innovation in biomedical research.
Researchers and taxpayers may see federal R&D dollars concentrated in a few large multi‑year awards, reducing funds available for investigator‑initiated grants and disadvantaging many applicants.
Recipients of XL01–XL03 awards are barred from competing for other federal research grants during award periods, limiting access to complementary funding and reducing overall research support flexibility.
Giving NIH broad discretion over eligibility, selection, and use of other-transaction authorities could weaken standard peer-review safeguards and create procurement or oversight risks for taxpayers and the research community.
Based on analysis of 2 sections of legislative text.
Creates an NIH X‑Labs Initiative to award multi‑year institutional grants (four XL categories) for breakthrough biomedical research and R&D infrastructure.
Introduced December 10, 2025 by Josh Harder · Last progress December 10, 2025
Creates a new NIH program to give long-term, large institutional awards to support breakthrough biomedical research and purchase R&D infrastructure. The program sets up four award types (XL01–XL04) with specified per-year funding ranges and multi-year award lengths, requires certain regranting and transparency rules for intermediary organizations, and leaves application, eligibility, and selection details to NIH rulemaking and appropriations.